Trial · NCT07586449
A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer
NCT07586449, Not yet recruiting, Zhejiang Cancer Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer. Trials, record NCT07586449. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07586449
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer
- NCT number
- NCT07586449
- Status
- Not yet recruiting
- Enrollment
- 500 participants, estimated
- Lead sponsor
- Zhejiang Cancer Hospital
- Conditions
- Ovarian Cancer (OvCa)
- Interventions
- Senaparib capsules(20mg)
- First posted
- 2026-05-14
- Last updated
- 2026-05-14
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and severity of Treatment-Related Adverse Events (TRAEs) according to NCI CTCAE v5.0 | 30 days after the last dose of fluzoparib | Incidence and severity of Treatment-Related Adverse Events (TRAEs) as assessed by the investigator. |
| Secondary | treatment patterns of senaparib | 2 years | the initial dose of senaprib 、incidence of dose reduction of senaparib 、treatment discontinuaiton of senaparib |
| Secondary | Progression free survival (PFS) | 6 years | Progression-free survival, defined as time from first administration senaparib to documented disease progression or death from any cause after baseline, whichever occurs first;. To assess clinical effectiveness of senaparib monotherapy or combination therapy involved in this study by assessment of progression free survival (PFS) in patients with Ovarian Cancer. Patients will be followed up once 3-6 months at least. |
| Secondary | overall survival (OS) | 6 years | Overall survival, defined as time from first administration senaparib to documented death. To assess clinical effectiveness of senaprib monotherapy or combination therapy involved in this study by assessment of overall survival (OS) in patients with Ovarian Cancer. Patients will be followed up once 3-6 months at least. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07586449
GET https://conductscience.org/api/trials/v1/NCT07586449/registered